Artal Group S.A. Decreases Position in SAGE Therapeutics Inc (SAGE)

Artal Group S.A. trimmed its holdings in SAGE Therapeutics Inc (NASDAQ:SAGE) by 50.0% in the 4th quarter, HoldingsChannel reports. The fund owned 75,000 shares of the biopharmaceutical company’s stock after selling 75,000 shares during the quarter. Artal Group S.A.’s holdings in SAGE Therapeutics were worth $12,353,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. New York State Common Retirement Fund increased its stake in SAGE Therapeutics by 258.0% during the 3rd quarter. New York State Common Retirement Fund now owns 149,564 shares of the biopharmaceutical company’s stock valued at $9,318,000 after purchasing an additional 107,782 shares in the last quarter. American Century Companies Inc. increased its stake in SAGE Therapeutics by 8.4% during the 3rd quarter. American Century Companies Inc. now owns 25,343 shares of the biopharmaceutical company’s stock valued at $1,579,000 after purchasing an additional 1,959 shares in the last quarter. Bank of New York Mellon Corp increased its stake in SAGE Therapeutics by 36.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,710,027 shares of the biopharmaceutical company’s stock valued at $168,834,000 after purchasing an additional 724,494 shares in the last quarter. Jane Street Group LLC bought a new stake in SAGE Therapeutics during the 3rd quarter valued at about $817,000. Finally, Stifel Financial Corp bought a new stake in SAGE Therapeutics during the 2nd quarter valued at about $401,000. Institutional investors own 95.47% of the company’s stock.

In other news, insider Stephen Kanes sold 44,000 shares of SAGE Therapeutics stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $177.18, for a total value of $7,795,920.00. Following the completion of the sale, the insider now directly owns 46,348 shares in the company, valued at $8,211,938.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Albert Robichaud sold 60,000 shares of SAGE Therapeutics stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $159.43, for a total transaction of $9,565,800.00. Following the completion of the sale, the insider now owns 152,759 shares of the company’s stock, valued at $24,354,367.37. The disclosure for this sale can be found here. Insiders sold 314,247 shares of company stock valued at $50,465,110 over the last quarter. Company insiders own 6.10% of the company’s stock.

A number of research firms have weighed in on SAGE. BidaskClub lowered shares of SAGE Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, February 13th. Needham & Company LLC raised their price objective on shares of SAGE Therapeutics from $86.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, November 10th. Canaccord Genuity set a $191.00 price objective on shares of SAGE Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 7th. BMO Capital Markets restated an “outperform” rating and set a $203.00 price objective on shares of SAGE Therapeutics in a research note on Thursday, December 7th. Finally, Stifel Nicolaus raised their price objective on shares of SAGE Therapeutics from $91.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, November 9th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and twelve have assigned a buy rating to the company’s stock. SAGE Therapeutics has a consensus rating of “Buy” and an average price target of $171.21.

Shares of SAGE Therapeutics Inc (SAGE) opened at $162.37 on Friday. SAGE Therapeutics Inc has a 12 month low of $59.50 and a 12 month high of $195.97. The company has a market cap of $7,445.28, a P/E ratio of -23.63 and a beta of 2.98.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://weekherald.com/2018/02/18/artal-group-s-a-decreases-position-in-sage-therapeutics-inc-sage.html.

SAGE Therapeutics Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SAGE Therapeutics Inc (NASDAQ:SAGE).

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply